JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

Continuing Questions About Esketamine 5 Years After Approval: Response to Ahmed et al.

Am J Psychiatry September 1, 2026 DOI: 10.1176/appi.ajp.20260182 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Peer reviewed
Topics	Esketamine

Abstract

Continuing Questions About Esketamine 5 Years After Approval: Response to Ahmed et al.

Comment on Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions. Am J Psychiatry September 1, 2026
Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study". Eur Neuropsychopharmacol June 5, 2026
Corrigendum to "Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study". Ther Adv Psychopharmacol May 19, 2026
Post‐approval analysis finds favorable safety for esketamine nasal spray The Brown University Psychopharmacology Update November 28, 2025
Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval. American Journal of Psychiatry September 10, 2025 24 citations